YH-12852 is under clinical development by Processa Pharmaceuticals and currently in Phase II for Diabetic Gastroparesis. According to GlobalData, Phase II drugs for Diabetic Gastroparesis have a 19% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how YH-12852’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
YH-12852 is under development for the treatment of chronic constipation, postoperative ileus, gastroparesis and diabetic gastroparesis. The drug candidate is a new chemical entity administered through the oral route. It acts by targeting 5-HT receptor. It was also under development for irritable bowel syndrome (IBS), functional dyspepsia and chronic constipation.
Processa Pharmaceuticals overview
Processa Pharmaceuticals, formerly Heatwurx, is a biopharmaceutical company which develops and commercializes drugs for the treatment of skin diseases and various cancer types. It is investigating its lead product candidate: PCS499 to treat necrobiosis lipoidica (NL), a chronic, disfiguring skin disorder; and to treat the side effects of radiation in patients with head and neck cancer. The PCS499 holds Orphan Drug designation for the treatment of NL. The company is evaluating PCS100, an anti-fibrotic and anti-inflammatory drug against idiopathic pulmonary fibrosis (IPF) and primary glomerulonephritis. It operates in the US. Processa Pharmaceuticals is headquartered in Baltimore, Maryland, the US.
For a complete picture of YH-12852’s drug-specific PTSR and LoA scores, buy the report here.